We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
59.00 | 3.18% | 1,913.00 | 1,916.00 | 1,918.00 | 1,920.00 | 1,861.00 | 1,861.00 | 522,491 | 16:35:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 22.08 | 4.24B |
Date | Subject | Author | Discuss |
---|---|---|---|
13/12/2016 13:54 | And another large buy | trier1 | |
13/12/2016 13:53 | Another 50k director buy... show so much confidence... | g2theary | |
12/12/2016 19:29 | No messing wi these guys,no tiddly buys like some directors | linton5 | |
12/12/2016 16:43 | Always good to see significant director buys | trier1 | |
08/12/2016 10:23 | *sorry yesterday's close | g2theary | |
08/12/2016 10:23 | Todays start price | g2theary | |
08/12/2016 09:54 | broadwood, I see from another source that 3,400 is Barclay's target price released today and 2,900 was their previous tp 09/09. What is the 1,702 figure? | jecs | |
08/12/2016 08:53 | g2 -Yes. On Broker Forecasts site. To access, you have to pay for early bird recs. | broadwood | |
08/12/2016 07:53 | Broadwood is that a broker comment from today? Where did you find that information? | g2theary | |
08/12/2016 07:38 | Barclays Capital Hikma Pharmaceuticals PLC 08/12/2016 Reiterates Overweight Overweight 0 2,900.00 3,400.00 1,702.00 | broadwood | |
07/12/2016 21:46 | Surly the big director buys are certainly a boast of confidence? These seem overweight IMO ... any other thoughts? | g2theary | |
07/12/2016 17:33 | Who is 8x p/e?... pfizer and lly are both about 30, abbv is at 15... Hikma is still a growing company and deserves a higher pe but 8 seems low even for an established low growth company.Someone is confident that this has more to drop however as the short interest is over 4% | coppertrader | |
07/12/2016 16:49 | Ask yourself why Hikma deserves to trade at 20 x 2017 earnings when the rest of the US sector trades at 8x. Healthy 22% ROCE? | farnesbarnes | |
05/12/2016 19:25 | Currently in 98th place with a share price of 1669... mcap of approx 4004, relegation occurs when companies drop below 110th | coppertrader | |
05/12/2016 12:56 | Another £6M for Darwazah... | g2theary | |
02/12/2016 19:49 | More director buys.. I'd be surprised if this goes much lower now... any points to suggest otherwise? | g2theary | |
29/11/2016 16:33 | I assume these will just about stay in the FTSE100 tomorrow anyone know for sure as I can't find any news regarding HIK on this matter? | g2theary | |
18/11/2016 20:49 | Egypt weakness? | r ball | |
17/11/2016 21:56 | Morgan Stanley | nortic 007 | |
17/11/2016 16:34 | rrb who or what is MS please? | ali47fish | |
17/11/2016 15:31 | Ask yourself why Hikma deserves to trade at 20 x 2017 earnings when the rest of the US sector trades at 8x. Read the full MS note and you'll see their analysis is based on lots of very optimistic assumptions. | rrb | |
16/11/2016 20:37 | They say 50% of a gain is given back. | r ball | |
15/11/2016 15:12 | A very bullish note | tsmith2 | |
15/11/2016 13:55 | Ftalphaville today's chat. | r ball | |
15/11/2016 12:51 | any details? | tsmith2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions